Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Biotechnology

Healthcare
$2.03 +2.84%

+$0.11 today

Market cap
$171.45M
Beta
0.97
P/E (TTM)
-5.5
EPS (TTM)
-$0.70
52W Low $1.35High $4.60

Volume 1.12M

Average 1.37M

ELDN Total Debt

Short-term and long-term borrowings combined.

Eledon Pharmaceuticals, Inc.NASDAQ: ELDN

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 36.9% from a year ago

Total debt stood at $555K at the end of Q1 FY2026, down 36.9% from a year earlier and down 13.4% from the prior quarter. Over 3 fiscal years it compounded at -4.9% a year.

Context

  • Total debt amounted to 0.4% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -36.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$555K-13.4% QoQ
Last fiscal yearDec 2025
$641K-32.8% YoY
Year agoMar 2025
$880K-36.9% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.9%——
1 year-32.8%——
3-year CAGR-4.9%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
641K USD
Year-over-year change
-32.8%
4-year CAGR
-4.4%

Total Debt vs competitors

How ELDN compares with its peers on the latest reported figures

  • ELDN's Mar 2026 total debt of $555K is the lowest of the 11 companies compared; the peer median is $28.87M.
  • Its year-over-year change of -36.9% is the 9th highest of 11, against a peer median of -1.8%.
  • Total debt amounts to 0.4% of total assets for ELDN, versus a peer median of 15.3%.
ELDN Competitors Peer median
Total Debt for ELDN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALLOAllogene Therapeutics, Inc.Mar 2026$81.05M -0.3%-6.3%20.5%
EDITEditas Medicine, Inc.Mar 2026$71.97M +131.2%+20.4%48.2%
HUMAHumacyte, Inc.Mar 2026$65.9M +315.8%+9.0%59.6%
TRDAEntrada Therapeutics, Inc.Mar 2026$49.75M -12.7%+25.2%14.8%
VYGRVoyager Therapeutics, Inc.Mar 2026$34.57M -17.7%+16.4%15.8%
ABEOAbeona Therapeutics Inc.Mar 2026$23.17M -3.4%+48.5%11.7%
PBYIPuma Biotechnology, Inc.Mar 2026$15.95M -74.1%-37.0%8.3%
ACHVAchieve Life Sciences, Inc.Mar 2026$14.95M +50.1%-2.6%45.2%
VNDAVanda Pharmaceuticals Inc.Mar 2026$13.07M +11.3%+4.2%3.0%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$634K -56.1%-35.4%0.2%
ELDNEledon Pharmaceuticals, Inc.Mar 2026$555K -36.9%-4.9%0.4%
Peer median (excluding ELDN) $28.87M-1.8%+6.6%15.3%

Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents84.83M56.41M4.61M20.55M22.81M
Short-term Investments0046.49M119.63M110.53M
Net Receivables0000514K
Inventory00000
Other Current Assets34K28K90K729K11K
Total Current Assets88.35M59.52M56.13M143.73M135.69M
Property, Plant & Equipment (Net)768K739K365K926K613K
Goodwill48.65M0000
Intangible Assets32.39M32.39M32.39M32.39M32.39M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets400K150K186K363K322K
Total Non-current Assets82.2M33.28M32.94M33.68M33.32M
Total Assets170.55M92.79M89.07M177.41M169.01M
Account Payables1.81M2.2M967K5.83M3.63M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.52M1.91M2M1.6M4.18M
Total Current Liabilities4.4M6.48M3.9M11.58M18.34M
Long-term Debt00000
Deferred Tax Liabilities1.75M01.75M2.18M2.19M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities01.75M76.21M44.87M67.11M
Total Non-current Liabilities2.15M2.14M77.96M47.69M69.58M
Total Liabilities6.55M8.61M81.86M59.27M87.92M
Common Stock14K14K24K60K75K
Retained Earnings(114.9M)(202.87M)(319.4M)(355.59M)(401.2M)
Accumulated OCI00026K24K
Other Stockholders Equity0(0)000
Minority Interest00000
Total Equity164M84.18M7.21M118.14M81.09M
Total Debt769K746K383K954K641K
Net Debt(84.06M)(55.66M)(4.23M)(19.6M)(22.17M)

Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Intrinsic Alpha fair value

Locked

Current Price

$2.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.